Jonathan Seidman is interested in dominant-acting mutations in sarcomere protein genes that cause hypertrophic cardiomyopathy in humans. The Seidman lab has made a murine model of this disease and demonstrated that these mutations lead to altered Ca2+ concentrations in myocytes. Ca2+ channel blockers reduce the hypertrophic response to sarcomere protein gene mutations in mice.